Current status of therapy for chronic myeloid leukemia: A review of drug development

Swami Padmanabhan, Saritha Ravella, Tyler J Curiel, Francis Giles

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Chronic myeloid leukemia (CML) has led the way for developing rational drug development in cancer. Most cases of CML diagnosed and treated in chronic phase are extremely well controlled with imatinib monotherapy, and primary resistance is very uncommon. Even though the treatment failure rate is low, the emergence of drug resistance and the lack of eradication of the hematopoietic stem cell clone has prompted a wave of drugs to address one or both these problems. Several clinical trials (Phase I and II) of dasatinib or nilotinib in the treatment of imatinib-resistant or -intolerant Ph chromosome-positive leukemia have already reported a remarkable rate of hematologic response greater than 90% for chronic-phase patients. These drugs minimize the risk of acquired drug resistance that is particularly seen within the first 24-36 months of therapy, and can prevent early failure in these patients, Furthermore, rational, noncross-resistant combinations that include a T3151 inhibitor and drugs that can eradicate the hematopoietic stem cell clone may extend the coverage to virtually all patients with bcr-abl. Here we review the 6-year impact of the 'magic pill', Gleevec®, (Glivec®), including the emerging problems with its treatment, the efficacy data of dasatinib and nilotinib and the very promising data of the newer generation of drugs for CML.

Original languageEnglish (US)
Pages (from-to)359-377
Number of pages19
JournalFuture Oncology
Volume4
Issue number3
DOIs
StatePublished - Jun 2008

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmaceutical Preparations
Hematopoietic Stem Cells
Drug Resistance
Clone Cells
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Magic
Treatment Failure
Leukemia
Chromosomes
Imatinib Mesylate
Neoplasms
Dasatinib
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

Keywords

  • CML
  • Cytogenic remission
  • Dasatinib
  • Imatinib
  • IRIS
  • Molecular remission

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Current status of therapy for chronic myeloid leukemia : A review of drug development. / Padmanabhan, Swami; Ravella, Saritha; Curiel, Tyler J; Giles, Francis.

In: Future Oncology, Vol. 4, No. 3, 06.2008, p. 359-377.

Research output: Contribution to journalArticle

Padmanabhan, Swami ; Ravella, Saritha ; Curiel, Tyler J ; Giles, Francis. / Current status of therapy for chronic myeloid leukemia : A review of drug development. In: Future Oncology. 2008 ; Vol. 4, No. 3. pp. 359-377.
@article{6bfa6c5a31fd4360881b30f3da92c590,
title = "Current status of therapy for chronic myeloid leukemia: A review of drug development",
abstract = "Chronic myeloid leukemia (CML) has led the way for developing rational drug development in cancer. Most cases of CML diagnosed and treated in chronic phase are extremely well controlled with imatinib monotherapy, and primary resistance is very uncommon. Even though the treatment failure rate is low, the emergence of drug resistance and the lack of eradication of the hematopoietic stem cell clone has prompted a wave of drugs to address one or both these problems. Several clinical trials (Phase I and II) of dasatinib or nilotinib in the treatment of imatinib-resistant or -intolerant Ph chromosome-positive leukemia have already reported a remarkable rate of hematologic response greater than 90{\%} for chronic-phase patients. These drugs minimize the risk of acquired drug resistance that is particularly seen within the first 24-36 months of therapy, and can prevent early failure in these patients, Furthermore, rational, noncross-resistant combinations that include a T3151 inhibitor and drugs that can eradicate the hematopoietic stem cell clone may extend the coverage to virtually all patients with bcr-abl. Here we review the 6-year impact of the 'magic pill', Gleevec{\circledR}, (Glivec{\circledR}), including the emerging problems with its treatment, the efficacy data of dasatinib and nilotinib and the very promising data of the newer generation of drugs for CML.",
keywords = "CML, Cytogenic remission, Dasatinib, Imatinib, IRIS, Molecular remission",
author = "Swami Padmanabhan and Saritha Ravella and Curiel, {Tyler J} and Francis Giles",
year = "2008",
month = "6",
doi = "10.2217/14796694.4.3.359",
language = "English (US)",
volume = "4",
pages = "359--377",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Current status of therapy for chronic myeloid leukemia

T2 - A review of drug development

AU - Padmanabhan, Swami

AU - Ravella, Saritha

AU - Curiel, Tyler J

AU - Giles, Francis

PY - 2008/6

Y1 - 2008/6

N2 - Chronic myeloid leukemia (CML) has led the way for developing rational drug development in cancer. Most cases of CML diagnosed and treated in chronic phase are extremely well controlled with imatinib monotherapy, and primary resistance is very uncommon. Even though the treatment failure rate is low, the emergence of drug resistance and the lack of eradication of the hematopoietic stem cell clone has prompted a wave of drugs to address one or both these problems. Several clinical trials (Phase I and II) of dasatinib or nilotinib in the treatment of imatinib-resistant or -intolerant Ph chromosome-positive leukemia have already reported a remarkable rate of hematologic response greater than 90% for chronic-phase patients. These drugs minimize the risk of acquired drug resistance that is particularly seen within the first 24-36 months of therapy, and can prevent early failure in these patients, Furthermore, rational, noncross-resistant combinations that include a T3151 inhibitor and drugs that can eradicate the hematopoietic stem cell clone may extend the coverage to virtually all patients with bcr-abl. Here we review the 6-year impact of the 'magic pill', Gleevec®, (Glivec®), including the emerging problems with its treatment, the efficacy data of dasatinib and nilotinib and the very promising data of the newer generation of drugs for CML.

AB - Chronic myeloid leukemia (CML) has led the way for developing rational drug development in cancer. Most cases of CML diagnosed and treated in chronic phase are extremely well controlled with imatinib monotherapy, and primary resistance is very uncommon. Even though the treatment failure rate is low, the emergence of drug resistance and the lack of eradication of the hematopoietic stem cell clone has prompted a wave of drugs to address one or both these problems. Several clinical trials (Phase I and II) of dasatinib or nilotinib in the treatment of imatinib-resistant or -intolerant Ph chromosome-positive leukemia have already reported a remarkable rate of hematologic response greater than 90% for chronic-phase patients. These drugs minimize the risk of acquired drug resistance that is particularly seen within the first 24-36 months of therapy, and can prevent early failure in these patients, Furthermore, rational, noncross-resistant combinations that include a T3151 inhibitor and drugs that can eradicate the hematopoietic stem cell clone may extend the coverage to virtually all patients with bcr-abl. Here we review the 6-year impact of the 'magic pill', Gleevec®, (Glivec®), including the emerging problems with its treatment, the efficacy data of dasatinib and nilotinib and the very promising data of the newer generation of drugs for CML.

KW - CML

KW - Cytogenic remission

KW - Dasatinib

KW - Imatinib

KW - IRIS

KW - Molecular remission

UR - http://www.scopus.com/inward/record.url?scp=47249138657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249138657&partnerID=8YFLogxK

U2 - 10.2217/14796694.4.3.359

DO - 10.2217/14796694.4.3.359

M3 - Article

C2 - 18518762

AN - SCOPUS:47249138657

VL - 4

SP - 359

EP - 377

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -